Based on Harrison's Principles, Ch.403-406 (Diagnosis, Management, Complications, Hypoglycemia)
Definition & burden
DM is a group of metabolic disorders sharing hyperglycemia, from reduced insulin secretion, decreased glucose utilization and increased glucose production.
Leading cause of ESRD, non-traumatic amputation and adult blindness; raises CVD risk.
Global: 463 M (2019) rising to 642 M by 2040; about 50% undiagnosed.
Glucose homeostasis
Fasting: low insulin + modest glucagon drive gluconeogenesis and glycogenolysis; glucose uptake by muscle/fat falls.
Fed: insulin rises, glucagon falls; muscle is the main site of postprandial uptake.
Insulin: proinsulin cleaved to insulin + C-peptide; C-peptide marks endogenous secretion.
Incretins (GLP-1, GIP) amplify glucose-dependent insulin secretion and suppress glucagon.
Classification (etiologic)
Type 1: immune-mediated beta-cell destruction.
Type 2: insulin resistance with relative insulin secretory defect.
Specific types: MODY and monogenic, neonatal DM, exocrine pancreas disease, endocrinopathies, drug-induced, infections.
Gestational DM (GDM).
Atypical forms
Ketosis-prone T2DM (often African American or Asian): DKA at onset, later controlled with oral agents.
Latent autoimmune diabetes of adult (5-10% phenotypic T2DM with GAD/ICA antibodies): likely to need insulin within 5 years.